On Thursday, Amgen, Inc. (NASDAQ:AMGN)’s shares inclined 2.87% to $160.12.
Amgen, Inc. (AMGN) declared that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically noteworthyimprovement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) contrast to those patients treated with BSC alone.
The Vectibix treatment arm further showed statistical significance for all key secondary endpoints counting OS in patients with wild-type RAS (absence of mutations in exons 2, 3 and 4 of KRAS and NRAS) mCRC.
In the Vectibix treatment arm, the observed adverse events comprised with the known Vectibix safety profile.
Full results will be presented to a future medical congress and for publication.
Colorectal cancer is the third most common cancer worldwide, with about 1.2 million cases occurring globally each year.1,2 In the U.S., colorectal cancer is the second leading cause of cancer-related deaths, with an estimated 132,700 new cases diagnosed in 2015.3,4 In Europe, colorectal cancer is the second most common cancer, with about 470,000 new cases each year.5
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The companys principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis.
Wendys Co (NASDAQ:WEN)’s shares gained 0.35% to $11.43.
Wendys Co (WEN) is working to give them one. Through its ninth annual Father’s Day Frosty® Weekend, Saturday, June 20 and Sunday, June 21, and the new #Share4Adoption initiative, Wendy’s and its customers will assist children in foster care find forever homes.
Funds raised through Wendy’s campaigns like these go to support the Dave Thomas Foundation for Adoption®, which works to assist find permanent, loving families for the more than 130,000 children in North America waiting in foster care to be adopted.
Father’s Day Frosty Weekend
Participating Wendy’s restaurants will celebrate Father’s Day Weekend, Saturday, June 20 and Sunday, June 21, with the Father’s Day Frosty Weekend program. Fifty cents from the sale of each Frosty over the weekend will be donated to Dave Thomas Foundation for Adoption to assist find families for the children waiting in foster care.
#Share4Adoption
Through August, customers will be served drinks in specially designed cups featuring half of a heart. Customers are asked to complete the heart on the cup with their hand, snap a picture and post it to Facebook, Instagram or Twitter with #Share4Adoption to support awareness of children in foster care.
The Wendy’s Company, through its auxiliaries, owns and franchises Wendy’s s restaurant system. The company is involved in operating, developing, and franchising a system of quick-service restaurants. As of May 26, 2015, its restaurant system comprised of about 6,500 franchised and company-operated restaurants worldwide. The company was formerly known as Wendy’s/Arby’s Group, Inc. and changed its name to The Wendy’s s Company in July 2011.
At the end of Thursday’s trade, Opko Health Inc. (NYSE:OPK)‘s shares surged 0.52% to $15.41.
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Bio-Reference Laboratories, Inc. (BRLI) (“Bio-Reference” or “the Company”) in connection with the sale of the Company to Opko Health, Inc. (OPK).
Under the terms of the transaction, Bio-Reference shareholders will receive 2.75 shares of Opko common stock for each share of Bio-Reference stock they own. The investigation concerns whether the Board of Bio-Reference breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Opko is underpaying for Bio-Reference shares.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, counting point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products comprise 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins.
Caterpillar Inc. (NYSE:CAT), ended its Thursday’s trading session with 0.18% gain, and closed at $87.41.
To help customers around the world optimize parts performance and further understand the health of their equipment, Caterpillar Inc. (CAT) has entered into a strategic alliance with Modustri, a provider of service and measurement technologies for use in the field. Caterpillar and Modustri will work together to develop innovations that enhance Cat® customers’ abilities to measure wear on parts like never before. In turn, these technologies will help customers optimize their fleets more effectively.
By utilizing web-based and mobile platforms, the companies will deliver simplified processes that provide customers accurate, immediate access to useful, real-time data while still in the field. This technology could save customers hundreds of hours and millions of dollars by proactively assisting Cat dealers and customer’s better measure wear rates and manage wear parts replacements — counting those from other suppliers.
In the coming months, Caterpillar will collaborate with Modustri and the Cat dealer network to create the latest Cat equipment wear administration technologies through web-based and mobile platforms, which will now be accessible for customer use.
Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives worldwide. The company’s Construction Industries segment offers backhoe, small wheel, skid steer, multi-terrain, compact track, medium and compact wheel, and track-type loaders; mini, wheel, and track excavators; track-type tractors; and select work tools, motor graders, telehandlers, soil compactors, and pipelayers, in addition to its related parts for the heavy and general construction, rental, mining and quarry, and aggregates markets. Its Resource Industries segment provides electric rope and hydraulic shovels; draglines; drills; highwall and longwall miners; hard rock vehicles; articulated, large mining, and off-highway trucks; large wheel loaders; wheel tractor scrapers; wheel dozers; machinery components; and electronics and control systems for use in mining and quarry applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
